ProfileGDS5678 / 1445271_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 64% 66% 74% 66% 67% 57% 61% 66% 64% 63% 68% 68% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8720964
GSM967853U87-EV human glioblastoma xenograft - Control 23.8308164
GSM967854U87-EV human glioblastoma xenograft - Control 34.0160466
GSM967855U87-EV human glioblastoma xenograft - Control 44.976674
GSM967856U87-EV human glioblastoma xenograft - Control 53.9295366
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0665967
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5555857
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6511961
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9703666
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8418264
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7418863
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1187768
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1274468
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9733766